Strive, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Strive, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $633.5K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $277.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $343.1K | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $829.6K | Mar 31, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51M | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | $4.22M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.65M | Mar 19, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($393.60M) | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | ($26.99M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($21.58M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($4.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($645.3K) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $14.9K | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($241.14M) | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | ($11.86M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($22.65M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($4.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($645.3K) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $14.9K | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $423.3K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $18.9K | Mar 31, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.98M) | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | ($18.21M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($21.60M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($3.81M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($602.8K) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $23.4K | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.0K | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | $0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $13.6K | Mar 31, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $745.53M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $28.20M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $373.0K | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $58.7K | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.29M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.86M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $153.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $219.2K | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $15.6K | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $582.44M | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | ($4.15M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $23.34M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $16.06M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $153.8K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $43.1K | Apr 2, 2024 |
| FY2022 | Dec 31, 2020 | $3.3K | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 19, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($474.05M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($49.15M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($5.56M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($627.1K) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $18.1K | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.50M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.16M | Mar 19, 2026 |
| FY2022 | Dec 31, 2022 | $137.2K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $33.7K | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | (11) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 19, 2026 |
| FY2025 | Sep 11, 2025 | (11) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |